Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06243237
Other study ID # 202201836A3
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 5, 2024
Est. completion date November 2025

Study information

Verified date December 2023
Source Chang Gung Memorial Hospital
Contact Yan Ru Ko
Phone 886972792003
Email b9403213@cgmh.org.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators propose a research design protocol to evaluate the efficacy of acupuncture in improving function recovery after acute intracranial hemorrhage.


Description:

Stroke is a major cause of death and disability. According to the Ministry of Health and Welfare in Taiwan, stroke accounted for 6.8% of all deaths and was the 4th leading cause of death in Taiwan in 2020. Stroke can be divided into acute, subacute, and chronic stages, and the initial severity of stroke affects recovery from sequelae. Therefore, how to effectively improve the sequelae and accelerate the recovery of patients through early interventions is an important issue. This study aimed to investigate the effect of early acupuncture treatment in the acute stage of hemorrhagic stroke. Subjects will be divided into two main groups by random assignment. The intervention group will be treated with traditional acupuncture, while the control group will be treated with pseudo-acupuncture(superficial acupuncture). The treatment frequency was 3 times a week for at least one week. Consciousness, neurological status and disability status were assessed before treatment, at the end of the first week, the second week and the third week, and biomarker were examined before and after treatment


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 2025
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria: - Diagnosis of hemorrhagic stroke by a specialist - Age over 20 years and below 85 years - GCS between 5-13 Exclusion Criteria: - Intracranial hemorrhage resulted from vascular anomalies - Pregnant patients - Intracranial tumor related hemorrhage - Other diseases that can cause neurological deficits, such as old cerebrovascular disease, poliomyelitis, cerebral palsy, spinal cord injury - Organ damage or terminal illness (heart or kidney failure or malignancy)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Acupuncture
Applied acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
Sham Acupuncture(Superficial Acupuncture)
Applied superficial acupuncture on specific acupoints in patient with acute intracranial hemorrhage.

Locations

Country Name City State
Taiwan Chang-Gung Memorial Hospital Keelung

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Barthel Index The Barthel Index is a scale used to measure performance in activities of daily living (ADL). The total score can range from 0 (complete dependence) to 100 (complete independence), providing a quantitative measure of an individual's functional independence. 3 weeks and follow-up for one year
Primary Muscle Power Muscle power is often assessed using a grading system. The most common is the Medical Research Council (MRC) Scale, which grades muscle strength on a scale from 0 to 5 and the lower scores mean the worse outcome. 3 weeks and follow-up for one year
Primary The Modified Rankin Scale The Modified Rankin Score (mRS) is a scale with scores ranging from 0 to 6, the higher scores mean the worse outcome. 3 weeks and follow-up for one year
Primary National Institute of Health Stroke Scale The total NIHSS score can range from 0 to 42, where a score of 0 means no stroke symptoms, and a higher score indicates a more severe stroke. 3 weeks and follow-up for one year
Primary Glasgow Coma Scale(GCS) The Glasgow Coma Scale(GCS) is a clinical scale used to reliably measure a person's level of consciousness. The total score can range from 3 to 15, and the lower scores mean the worse outcome. 3 weeks and follow-up for one year
Primary Karnofsky Performance Scale The Karnofsky Performance Score (KPS) ranking runs from 100 to 0, where 100 is "perfect" health and 0 is death. 3 weeks and follow-up for one year
Secondary Pulse analysis system (PPAS-96)(Sphygmography) Pulse analysis system (PPAS-96) can realize the digitization of pulse wave graphics, establish a pulse wave database (scale unit: Hertz, Hz). 3 weeks and follow-up for one year
Secondary Completed blood count (CBC) Measuring the amounts of red blood cells (RBC, million/µL), white blood cells (WBC, 1000/µL), platelets (Plt, 1000/µL), along with the hemoglobin (Hb, g/dL) and hematocrit (Hct, %) values via automated hematology analyzer. 3 weeks and follow-up for one year
Secondary White blood cells differential count Calculating the percentage of each type of white blood cell (WBC): Segment(%), Band(%), Lymphocyte(%), Monocyte(%), Eosinophil(%), Basophil(%) 3 weeks and follow-up for one year
Secondary C reactive protein (CRP) Measuring the level of C reactive protein in blood. (CRP, mg/L) 3 weeks and follow-up for one year
Secondary Albumin Measuring the level of albumin in blood. (Alb, g/dL) 3 weeks and follow-up for one year
Secondary Blood urea nitrogen (BUN) Measuring the level of blood urea nitrogen. (BUN, mg/dL) 3 weeks and follow-up for one year
Secondary Creatinine Measuring the level of creatinine in blood. (Crea, mg/dL) 3 weeks and follow-up for one year
Secondary Sodium Measuring the level of sodium in blood. (Na, milliequivalent (mEq)/L) 3 weeks and follow-up for one year
Secondary Potassium Measuring the level of potassium in blood. (K, milliequivalent (mEq)/L) 3 weeks and follow-up for one year
See also
  Status Clinical Trial Phase
Recruiting NCT03969732 - Multimodal Biomarkers for Diagnosis and Prognosis in CAA Phase 3
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Recruiting NCT03950076 - EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Phase 4
Completed NCT03542656 - Application of Amyloid PET in Cerebral Amyloid Angiopathy Phase 3
Active, not recruiting NCT05626504 - Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Recruiting NCT03495206 - Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet Phase 1
Not yet recruiting NCT04229758 - Restarting Anticoagulation After Traumatic Intracranial Hemorrhage Phase 3
Recruiting NCT02135783 - Decompressive Craniectomy Combined With Hematoma Removal to Treat ICH N/A
Enrolling by invitation NCT02050971 - Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates Phase 1
Completed NCT01193270 - Vitamin E for Extremely Preterm Infants Phase 1
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Completed NCT03364634 - Intracranial Pressure After Decompressive Craniectomy N/A
Completed NCT00226096 - Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage N/A
Recruiting NCT06081283 - Antiseizure Medication in Seizure Networks at Early Acute Brain Injury Phase 4
Recruiting NCT04459806 - Intracranial PrEssure Time dOse (ImPETO)
Recruiting NCT05874050 - Arterial Pressure and Surgical Hemostasis in Elective Neurosurgery.
Not yet recruiting NCT05138341 - Minimal Invasive Surgical Intracerebral Hemorrhage Removal N/A
Terminated NCT03660618 - LSFG-SKIN, Laser Speckle Flowgraphy N/A
Recruiting NCT06370520 - Screening Emotions in Adolescents at the Hospital for mTBI